Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis

Journal of Bone and Mineral Research

Volumn 27, Issue 7, 2012, Pages 1487-1493

  Boonen, Steven ^a   Eastell, Richard ^b   Su, Guoqin ^c   Mesenbrink, Peter ^c   Cosman, Felicia ^d   Cauley, Jane A ^e   Reid, Ian R ^f   Claessens, Frank ^a   Vanderschueren, Dirk ^a   Lyles, Kenneth W ^g,h   Black, Dennis M ⁱ  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

^d HELEN HAYES HOSPITAL   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f UNIVERSITY OF AUCKLAND   (New Zealand)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h Carolinas Center for Medical Excellence   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bone mineral density; Fractures; Postmenopausal osteoporosis; Reaction time; Zoledronic acid

Indexed keywords

PLACEBO; ZOLEDRONIC ACID;

ARTICLE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG SAFETY; FRACTURE; HUMAN; INCIDENCE; OSTEOPOROSIS; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; STATISTICAL ANALYSIS;

AGED; AGED, 80 AND OVER; ALGORITHMS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMIDAZOLES; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PLACEBOS; PROPORTIONAL HAZARDS MODELS; RISK; TIME FACTORS;

EID: 84862490476     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1605     Document Type: Article

References (24)

1. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-41. (Pubitemid 26411651)
2. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Voqt T, Wallace R, Yates AJ, LaCroix AZ. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-82. (Pubitemid 29014065)
3. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344-52. (Pubitemid 29483192)
4. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11:83-91. (Pubitemid 30099515)
5. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR. Fracture Intervention Trial. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000;85:4118-24. (Pubitemid 32055362)
6. Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone P, Grauer A, Barton I, Boonen S. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;74:129-35. (Pubitemid 38263854)
7. Huas D, Debiais F, Blotman F, Cortet B, Mercier F, Rousseaux C, Berger V, Gaudin AF, Cotté FE. Compliance and treatment satisfaction of post menopausal women treated for osteoporosis. Compliance with osteoporosis treatment. BMC Women's Health. 2010;10:26.
8. Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B. Early discontinuation of treatment for osteoporosis. Am J Med. 2003;115:209-16. (Pubitemid 37338146)
9. Roux C, Seeman R, Eastell R, Adachi J, Jackson RD, Felsenberg D, Songcharoen S, Rizzoli R, DiMunno O, Horlait S, Valent D, Watts NB. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin. 2004;20:433-9. (Pubitemid 38525150)
10. Rabenda V, Mertens R, Fabri V, Vanoverloop J, Sumkay F, Vannecke C, Deswaef A, Verpooten GA, Reginster JY. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int. 2008;19:811-8.
11. Devine J, Trice S, Finney Z, Yarger S, Nwokeji E, Linton A, Davies W. A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System. Osteoporos Int. 2011 July 23. [Epub ahead of print].
12. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81:1013-22. (Pubitemid 44175011)
13. Roux C, Fechtenbaum J, Kolta S, Isaia G, Andia JB, Devogelaer JP. Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. Ann Rheum Dis. 2008;67:1736-8.
14. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR. HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-22. (Pubitemid 46698462)
15. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S. HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799-809. (Pubitemid 350044800)
16. World Medical Association. Declaration of Helsinki: ethical principle for medical research involving human subjects. 41th WMA General Assembly; September 1989; Hong Kong. Available at: http://www.wma.net/en/30publications/10policies/ b3/index.html. Accessed 24 January 2012.
17. Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone. 2007;40:1238-43. (Pubitemid 46550991)
18. Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R. Multiple Outcomes of Raloxifene Evaluation Investigators. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002;87:3609-17. (Pubitemid 34879503)
19. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006;38:617-27.
20. Gallagher AM, Rietbrock S, Olson M, van Staa TP. Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res. 2008;23:1569-75.
21. Hadji P, Claus V, Ziller V, Intorcia M, Kostev K, Steinle T. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int. 2012;23:223-31.
22. Hoer A, Seidlitz C, Gothe H, Schiffhorst G, Olson M, Hadji P, Häussler B. Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis. Patient Prefer Adherence. 2009;3:25-30.
23. Penning-van Beest FJA, Erkens JA, Olson M, Herings RMC. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int. 2008;19:511-7.
24. Adachi JD, Josse RG, Russell RG. If you don't take it, it can't work: the consequences of not being treated or nonadherence to osteoporosis therapy. Ther Clin Risk Manag. 2011;7:181-98.